Trastuzumab Deruxtecan (T-Dxd; Ds-8201) Vs Investigator'S Choice Of Chemotherapy In Patients With Hormone Receptor-Positive (Hr+), Her2 Low Metastatic Breast Cancer Whose Disease Has Progressed On Endocrine Therapy In The Metastatic Setting: A Randomized, Global Phase 3 Trial (Destiny-Breast06)